Interview 13 Dec 2016 Meet the French Seaweed Startup rethinking Bioplastics Algopack is a French startup manufacturing bio-based materials made from brown algae. It is the first to use it to develop a new generation of bioplastics. Founded by Rémy Lucas in 2010 and managed by David Coti, Algopack offers a breakthrough innovation using marine natural resources as a unique renewable biomass. The company hopes to […] December 13, 2016 - 3 minutesmins - By Nicolas Sainte-Foie Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2016 Paris takes the lead in Digital Health for Diabetes Type 2 The smell of freshly baked baguettes and good news from the capital have brought us this week to France. Voluntis has received market approval for a device that could change the life of millions of people with diabetes type 2, check out this cool company! City: Paris, France Founded: 2001 Employees: 100 Financial data: Total of €29.8M raised in […] December 9, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2016 Our Startup Battle Winner uses CRISPR in a Whole New Way Eligo Bioscience came out on top in the Startup Battle at Labiotech Refresh, watch the founder’s pitch to see how! CRISPR can be used to cut and replace virtually any gene, which has fueled a fierce patent battle over the rights to use it for gene therapy in humans. Eligo Bioscience, however, focuses on using this powerful tool to […] December 9, 2016 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2016 Sanofi Jumps into the Biosimilars Market aiming for Asia Sanofi is joining the biosimilars trend to challenge Roche’s best-selling biological with a partnership that aims to take over the Chinese cancer market. Sanofi is going after the €6.8B ($7.3B) that Roche’s Rituxan/MabThera (rituximab), the second top-selling biological, made last year in revenues. The French pharma has signed a deal worth up to €219M ($236M) […] December 6, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 1 Dec 2016 UPDATE: The HIV Frontier starts Phase III Vaccine trials in South Africa Update (01/12/2016): The HVTN 702 trial has been started, making it the first HIV vaccine efficacy study in 7 years worldwide. Results are expected in late 2020. Originally published 25/07/2016 A Phase IIb/III trial for an experimental HIV vaccine just started in South Africa. The therapy, co-funded by the NIH and the Gates Foundation, is a combination […] December 1, 2016 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 30 Nov 2016 This was Labiotech Refresh! Check our recap and highlight video! Six months have passed since the last time we opened the doors for the very first Labiotech Refresh, Europe’s most refreshing Biotech Conference. Last week we launched our second edition live from Le Machine du Moulin Rouge in Paris! Were you not able to attend? Don’t worry! Here is our highlight video: And here’s also a […] November 30, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 Nov 2016 Treating the Inner Ear: a solution for Vertigo is on the way! Sensorion is about to start Phase II trials to treat acute severe vertigo. What makes the inner ear such an attractive target for biotech? Sensorion is a French biotech developing treatments for inner ear pathologies, including vertigo, tinnitus and hearing loss. The company has just announced the start of Phase II trials with SENS-111, a drug candidate […] November 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 22 Nov 2016 Sanofi quietly leaves Bladder Cancer Patients in the lurch Sanofi is halting the production of the main bladder cancer drug. In response, doctors are pressuring regulatory agencies to take action against this instance of a widespread issue of drug shortages. Sanofi Pasteur announced last week that it will be shutting down the production of the cancer drug BCG (TheraCys and ImmuCyst) in mid-2017. This drug […] November 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2016 Microbiomics recruited for Immuno-Oncology in a Huge New Partnership What if the bacteria in your gut could help fight cancer? Enterome is partnering with Bristol-Myers Squibb to explore this possibility and develop microbiome-related therapeutics and diagnostics for immuno-oncology. Enterome, one of the coolest biotechs in Paris, specializes in the isolation of bacteria and microbial targets linked to immune modulation and inflammation. With an impressive […] November 16, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2016 RNAi Therapy is Back: Sanofi is firmly on board to treat Hemophilia Sanofi Genzyme is offering Alnylam up to €93M ($100M) to co-develop and launch a revolutionary RNAi therapy for hemophilia. But is RNAi really such a good investment? Sanofi Genzyme signed a deal with Alnylam back in 2014 to develop RNAi therapies. Now, despite the general discouragement in RNAi technology, Sanofi has decided to go ahead and […] November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2016 Red Blood Cells as Cancer Drug Carriers: Market Approval gets Delayed Erytech will have to provide additional data before re-applying for market approval in Europe for Graspa. This leukemia therapy uses red blood cells to deliver an enzyme that starves tumors to death. Erytech is a biotech from Lyon with a visionary approach to treat cancer: using red blood cells as drug carriers. Last year, the company […] November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2016 Meet one of the Most Impressive French Biotech Entrepreneurs The previous executive profiles we did, namely on Joern Aldag and Philippe Dro, are hard acts to follow, but Bernard Gilly was more than up to it. Bernard has a broad set of achievements for a broad set of lessons and takeaways. Here are the major ones. You might have seen Bernard Gilly’s name in the […] November 14, 2016 - 6 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email